Abstract 160P
Background
Hormonal BCs are characterized by the expression of hormonal receptors (estrogen or progesterone). They can be treated with endocrine therapy (ET) including anti-aromatase inhibitors (AI) and/or anti-cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. However, such treatments can cause cancer cells to mutate and impact genes such as ESR1, PIK3CA and/or AKT1, which are associated with ET resistance. By establishing the baseline level of these mutations in Formalin-Fixed Paraffin-Embedded (FFPE) DNA from patients with advanced or metastatic BC treated with AI and CDK4/6 inhibitors, the CICLADES-CE study, ancillary to CICLADES trial aims to identify genomic signatures to be monitored during follow-up of clonal evolution.
Methods
Twenty FFPE samples from female patients diagnosed with advanced BCs and treated with AI were qualified, selected and microdissected. The AllPrep® DNA/RNA FFPE kit (Qiagen) was used to extract DNA. A method of Hybridization Capture-based Target Enrichment with a 516-gene panel was used on the NextSeq 550® (Illumina) for sequencing. Single nucleotide variants, copy number variants and telomere length were detected. Data obtained were then analyzed to identify highly mutated genes, specific mutations in genes of interest and genomic signatures as described by Alexandrov et al, 2013.
Results
Among 20 samples, 19 reached the quality criteria to be sequenced. We showed that several genes involved in the PI3-Kinase pathway were mutated across several samples, but no relevant mutations of AKT and ESR1 were found at baseline. Among the samples, 3 genomic signatures were detected, corresponding to validated COSMIC (Catalogue of Somatic Mutations in Cancer) signatures 5, 6 and 30. Those signatures are associated with DNA damage repair and deficiency of the base excision repair system.
Conclusions
The signatures found are a mirror of the samples origin and the type of fixation used. With this information we have created a focused gene panel to be used for ctDNA follow-up analysis. It also provides us with a clear baseline mutational landscape for the profiling of the rest of the CICLADES cohort.
Editorial acknowledgement
Clinical trial identification
CIrCuLAting Dna ESr1 Gene Mutations Analysis (CICLADES): NCT03318263 First posted: October 23, 2017.
Legal entity responsible for the study
Institut de Cancérologie de Lorraine, Service de Biopathologie, CNRS UMR 7039 CRAN Université de Lorraine.
Funding
Cancéropôle de l'Est and AstraZeneca.
Disclosure
V. Massard: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Eli Lilly, Pfizer, Bayer; Financial Interests, Personal, Invited Speaker: Gilead Sciences, Astellas Pharma, Janssen Pharmaceuticals, Laboratoires Pierre Fabre; Financial Interests, Institutional, Funding: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract